GSK plc 6-K, filed Aug 31, 2021
GSK plc (GSK)
6-K
2021-08-31
For: 2021-08-31
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on August 31, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 31 August 2021, London, UK and Seoul, Republic of
Korea
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19
vaccine candidate
● Advance to Phase 3 follows positive interim Phase
1/2 immunogenicity and safety data
● Global clinical trial will evaluate vaccine
candidate GBP510 against the AZ/Oxford COVID-19
vaccine
● Aim is for global supply through the COVAX
facility in the first half of 2022, subject to data and regulatory
review
SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced
the initiation of a Phase 3 clinical study of SK's
COVID-19 vaccine candidate, GBP510, in combination with GSK's
pandemic adjuvant following positive interim Phase 1/2
results.
The randomised, active-controlled global trial will enrol around
4,000 participants from a range of countries and will aim to
evaluate GBP510's safety and immunogenicity compared to an active
comparator - the AstraZeneca/Oxford University COVID-19 vaccine.
The study will be one of the first global Phase
3 trials to compare two different COVID-19 vaccine
candidates.
Jaeyong Ahn, CEO, SK bioscience said, "We are grateful that we were
able to advance to the Phase 3 study with the unprecedented support
of global initiatives, including GSK, Coalition
for Epidemic Preparedness Initiative (CEPI), and the Bill &
Melinda Gates Foundation (BMGF). Taking this important step towards
overcoming the global pandemic situation, SK and GSK will bring our
technical expertise together for the development of an adjuvanted
protein-based vaccine candidate, GBP510."
Thomas Breuer, Chief Global Health Officer, GSK said, "While many
countries have made good progress with vaccination, there remains a
need for accessible and affordable COVID-19 vaccines to ensure
equitable access and to protect people across the
world. We are pleased to contribute with GSK's pandemic
adjuvant and to be working with SK to deliver the vaccine at scale
via COVAX if it is approved."
The advance to Phase 3 study follows positive interim Phase 1/2
data which showed that all participants who received the adjuvanted
vaccine candidate developed strong neutralizing antibody responses,
demonstrating a 100% seroconversion rate. Neutralizing antibody
titres were between five and a maximum of eight times higher
compared to sera from people recovered from COVID-19. No safety
concerns have been identified to date in this ongoing
study.
GBP510 is a self-assembled nanoparticle vaccine candidate
targeting the receptor binding domain of the SARS-CoV-2 Spike
protein, combined with GSK's pandemic adjuvant. The antigen is
being developed by SK in collaboration with the Institute for
Protein Design (IPD) at the University of Washington with support
from BMGF and CEPI as part of the 'Wave 2' vaccine investment
project to develop more accessible and affordable COVID-19
vaccines.
Results from the Phase 3 study are expected in the first half of
2022 after which, subject to positive results and regulatory
approval, the vaccine is expected to be supplied at scale worldwide
through the COVAX facility.
GSK commitment to tackling COVID-19
GSK's response to COVID-19 has been one of the broadest in the
industry, with two potential treatments in addition to our vaccine
candidates in development.
GSK is collaborating with several organisations on COVID-19
vaccines by providing access to our pandemic adjuvant. As well as
working with SK, we are collaborating with Sanofi and Medicago
to develop adjuvanted, protein-based vaccine candidates,
and all are now in Phase 3 clinical
trials. The use of an adjuvant can be of particular importance in a
pandemic since it may reduce the amount of vaccine protein required
per dose, allowing more vaccine doses to be produced and
contributing to protect more people in need.
GSK is also working with mRNA specialist, CureVac, to jointly
develop next generation, optimised mRNA vaccines for COVID-19 with
the potential to address multiple emerging variants in one
vaccine.
GSK is also exploring potential therapeutic or treatment options
for COVID-19 patients. We are collaborating with Vir Biotechnology
to develop existing and identify new anti-viral antibodies that
could be used as therapeutic or preventive options for COVID-19.
Sotrovimab, a monoclonal antibody for the early treatment of
COVID-19 in adults at high risk of hospitalisation, received
Emergency Use Authorization (EUA) from the US Food and Drug
Administration (FDA) in May 2021. We are also assessing whether an
investigational monoclonal antibody, otilimab, can help severely
ill COVID-19 patients aged over 70 who experience an overreaction
of their immune system.
About SK bioscience
SK bioscience is an innovative biopharmaceutical company
specialized in the vaccine area. By leveraging strengths in
cutting-edge vaccine development technologies, we have been
dedicated to human health from prevention to cure
across the globe. With the collaboration of domestic and
international governments, regulatory agencies, healthcare
providers and medical experts, our colleagues are passionately
committed to provide affordable and high-quality vaccines to those
who need them and improve the health
care environment.
For more information, please visit
https://www.skbioscience.co.kr/en/main
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kristen
Neese
|
+1 804
217 8147
|
(Philadelphia)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such
factors include, but are not limited to, those described in the
Company's Annual Report on Form 20-F for 2020 and any impacts of
the COVID-19 pandemic.
Registered
in England & Wales:
No.
3888792
Registered Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
31, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|